Glioma Group

Dr Chris Jones’ group investigates ways to translate basic molecular pathology findings into improved clinical outcomes for children with cancer.

Our group is primarily focused on high grade gliomas which arise in children, either supratentorially, or within the brainstem.

The Jones laboratory is primarily focused on high grade gliomas which arise in children, either supratentorially, or within the brainstem. These tumours appear to have key biological and clinical distinctions, both to each other, and histologically similar lesions in adults.

To this end we have current projects focussed on:

  • Genomic and epigenomic profiling of glial tumours of childhood, including large retrospective studies, prospective clinical trial cohorts, and rare entities such as infant glioma and gliomatosis cerebri
  • Model development and preclinical screening of paediatric glioma subgroups, with specific projects focussing on the development of novel therapies directed against ACVR1, histone H3.3 G34R/V and ATRX mutations
  • Intratumoral heterogeneity and subclonal co-operation between distinct cancer stem cell subpopulations, with a view to using disruption of these interactions as a novel area for therapeutic intervention


High-grade gliomas in children share similar histopathological features and a dismal prognosis to those that arise in adults, with a median survival of 15-18 months for cerebral hemispheric tumours and 9-12 months for diffuse intrinsic pontine glioma (DIPG).

Bulk tumour molecular profiling has recently provided important insights into the biological differences associated with high grade gliomas arising at different ages and in different locations.

We and others have identified unique genetic drivers of paediatric high-grade glioma, not present in the adult disease, which illustrate previously unappreciated connections between chromatin regulation, developmental signalling and cancer.

Distinct anatomical distributions of childhood tumours marked by these specific driver mutations points at important differences in the selective pressures vary between regions of the developing brain.

One of the primary goals of my laboratory is to better understand the function of these genetic alterations in the context of paediatric gliomagenesis and to use this mechanistic insight to develop novel therapies for children with these tumours.

Professor Chris Jones

Head of Division:

Glioma Professor Chris Jones

Chris Jones is the Head of Division for Molecular Pathology and heads the Glioma Group whose research aims to find the genes which drive the development of childhood brain tumours. He is Professor of Childhood Brain Tumour Biology, and Preclinical Chair of the international CONNECT consortium.

Researchers in this group

.

Phone: +44 20 3437 6957

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6664

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

Dr Julia Cockle is an NIHR-funded Academic Clinical Lecturer at the Institute of Cancer Research. She works as part of the Glioma Group, and her research explores the tumour immune microenvironment of paediatric brain tumours in order to facilitate selection of immunotherapies.

.

Phone: +44 20 3437 6070

Email: [email protected]

Location: SuttonChelsea

.

Phone: +44 20 3437 6384

Email: [email protected]

Location: Sutton

.

Phone: +44 20 8722 4540

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 3635

Email: [email protected]

Location: Sutton

.

Phone: +44 20 8722 4138

Email: [email protected]

Location: Sutton

I am Executive Assistant to Professor Chris Jones, Interim Head of the Division of Molecular Pathology. I also act as the liaison point for the Divisional Team Leaders and their teams to ensure smooth running of the administration and oversight of the Division.

.

Phone: +44 20 3437 6165

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6199

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Chelsea

.

Phone: +44 20 8722 4225

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6169

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6176

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 3649

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6166

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

Haider Tari profile picture .

Email: [email protected]

Location: Sutton

Professor Chris Jones's group have written 197 publications

Most recent new publication 4/2025

See all their publications

Recent discoveries from this group

02/12/25

The Institute of Cancer Research, London, has been honoured for its vital role in advancing research-driven care for children with brain tumours.

The Royal Marsden Hospital, St George's Hospital and King's College Hospital with The Institute of Cancer Research, London, as the South London Paediatric Neuro-Oncology Network, has announced that it has been designated a Tessa Jowell Centre of Excellence for Children.

The South London Paediatric Neuro-Oncology Network is one of four UK paediatric neuro-oncology centres to be awarded the designation today by the Tessa Jowell Brain Cancer Mission (TJBCM).

The designation will be confirmed by Ashley Dalton, the health minister, at an event in London.

Recognition of excellence and rapid improvement

The event will also mark the launch of the new Tessa Jowell Academy for Paediatrics, a national hub for training and collaboration in paediatric neuro-oncology, providing an opportunity for the South London Paediatric Neuro-Oncology Network to share examples of excellent practice with other children’s neuro-oncology centres around the UK.

The designation of four new Tessa Jowell Centres of Excellence for Children, joining the six previously designated, now means that two thirds of the UK population is now in the catchment area of a Tessa Jowell Centre of Excellence for Children. This is a major step towards ensuring that children receive excellent care irrespective of where they live. 

The South London Paediatric Neuro-Oncology Network was designated as a Tessa Jowell Centre of Excellence after working for the past 18 months to implement innovative new solutions. The centre’s neuro-oncology team showed an exceptional commitment to service development, bringing together a wide number of specialties to deliver impactful changes. 

A rigorous review process

The designation follows a rigorous review process which examined multiple areas of the patient pathway in detail, together with patient feedback collected by The Brain Tumour Charity. TJBCM’s panel of neuro-oncology experts particularly commended the South London Paediatric Neuro-Oncology Network for excellence in their:

  • Strong integration of teams across the network, highlighted by excellent nurse outreach and collaboration, providing patients with wrap-around care throughout their treatment journey.
  • Excellent imaging service, including an exemplary training programme that supports the development of highly skilled specialists.
  • Comprehensive approach to follow-up support with a dedicated ‘Back on Track’ late effects clinic and aftercare service. 
  • Innovative use of the MyMarsden app to promote patient autonomy, streamline communication, and provide ongoing and meaningful post-treatment support.
  • Exemplary integration of education support into clinical care, supported by the outstanding nursing and play specialist teams, ensuring comprehensive support for patients’ cognitive development and reintegration to school. 
  • Strong research activity and involvement with national and international trials, highlighting the South London Paediatric Neuro-Oncology Network’s contribution to national innovation and evidence generation.  

 

All areas of the South London Paediatric Neuro-Oncology Network’s service now meet the Tessa Jowell Standards of Excellence, thanks to the hard work of the paediatric neuro-oncology team in delivering significant service developments, reflecting the team’s strong commitment to patient-centred care. 

Centre of Excellence designation confirms the South London Paediatric Neuro-Oncology Network’s commitment not only to high-quality care today but to continually improving services for children in the years ahead.

Professor Chris Jones, Professor of Childhood Brain Tumour Biology at the Institute of Cancer Research said:

“Being designated as a Tessa Jowell Centre of Excellence for Children is a tremendous achievement for our entire network. This recognition reflects not only the dedication of teams from The Institute of Cancer Research, London, The Royal Marsden, St. George's University Hospital and King's College Hospital, but also the power of collaboration across centres. By working together, we can accelerate discoveries and translate them into better treatments for children with brain tumours—providing hope for families facing the most challenging diagnoses.”

Nicky Huskens, Chief Executive of the Tessa Jowell Brain Cancer Mission, said:

“Congratulations to everyone in the South London Paediatric Neuro-Oncology Network. Designation as a Centre of Excellence for Children underlines the strength of services for children with a brain tumour. The neuro-oncology team has shown its firm dedication to improving care and an impressive capacity to make meaningful changes in a tight timeframe. We look forward to continuing to work with them, helping to share their innovations and best practice with colleagues across the country.”